These differences persisted over time.An increase in bone or joint pain was more pronounced, particularly in the short term, in patients who received exemestane plus ovarian function suppression than in patients who received tamoxifen plus ovarian function suppression.Changes in global QOL indicators from baseline were small and similar between treatments over the 5 years.[59][Level of evidence A3] Patients who received tamoxifen plus ovarian function suppression were more affected by hot flashes and sweats over 5 years than were those who received exemestane plus ovarian function suppression, although these symptoms improved.